FDA Approves New Vaccine for Prevention of Cervical Cancer
in a statement released by Mr Bakainaga Andrew, the WHO advisor on vaccines development yesterday, disclosed that The World Health Organisation (WHO) has defended the safety of the controversial cervical cancer vaccine, currently a subject of a lawsuit in Japan Courts,
saying there is no evidence of life treating side effects related to its use as is believed, and indicated that the Global Advisory Committee Vaccines Safety (GACVS) has not found any safety issues that would alter its recommendations for the use of the vaccine, adding that “This risk, which is small, if it exists at all, needs to be seen in the context of the long-lasting cancer-prevention benefits of HPV infection,” the statement read in part. Citing results of a recent retrospective cohort study from the French National Agency for Medicines and Health Products Safety on autoimmune conditions following Human Papilla Virus(HPV) vaccination, the statement indicated that the risk in the first few months after vaccination was very small (1 per 100,000 vaccinated children). The WHO country office response comes after the Daily Monitor published a story last week indicating that Gardasil, a vaccine that immunises 10- year-old girls against cervical cancer, is one of the vaccines cited in a high-profile Japanese lawsuit.
. However, WHO also delinked the connection of the vaccine to concerns about complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS).